PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of neurologyNeurologyAmerican Academy of Neurology
 
Neurology. 2012 September 11; 79(11): 1116–1123.
PMCID: PMC3525301

C-reactive protein and familial risk for dementia

A phenotype for successful cognitive aging
Jeremy M. Silverman, PhD,corresponding author

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. 1. Journal of Alzheimer’s Disease, associate editor, 2011

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. 1. NIH, P01-AG02219,2005-2010 2. NIH, R01-MH065554, 2005-2012 3. Alzheimer’s Association, NA, 2007-2011 4. Department of Veterans Affairs, Merit Award, 2009-2012

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
James Schmeidler, PhD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. Jewish Home and Hospital; Vitals, Inc.

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. New York State Office of Alcoholism and Substance Abuse Services; New York/New Jersey High Intensity Drug Trafficking Area

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. Alzheimer’s Association; American Federation for Aging Research

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Michal S. Beeri, PhD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NIH funding

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. The Helen Bader Foundation approved funds to lay the infrastructure for the Israel Registry for Alzheimer’s Prevention (IRAP).

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Clive Rosendorff, MD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. Teva Pharmaceuticals, Expert Witness, 2011 Glenmark Pharmaceuticals, Expert Witness, 2011
Mary Sano, PhD,

Scientific Advisory Boards:

  1. Medivation, Takeda, QR Pharma, Sanofi Aventis, Eisai: Scientific Advisory Board NIA DSMB member to ASPREE study Alzheimer Association Medical and Scientific Advisory Board Member

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. Bayer; Bristol Meyer Squibb; Elan; Medivation; Medpace; Pfizer; Takeda; United Biosource

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NIA; NCRR; VA

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Hillel T. Grossman, MD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. 1. Humanetics, 2. Medivation, 3. Polyphenolics

Research Support, Government Entities:

  1. NCAAM; NIA; VA MERIT as PI or sub-I

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
José R. Carrión-Baralt, PhD, MPH,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Irina N. Bespalova, PhD,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. VA Merit Award to J.M. Silverman

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
Rebecca West,

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. NONE

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. NONE

Research Support, Government Entities:

  1. NONE

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE
and Vahram Haroutunian, PhD

Scientific Advisory Boards:

  1. NONE

Gifts:

  1. NONE

Funding for Travel or Speaker Honoraria:

  1. Non-Profit, Human Amyloid Imaging, Honorarium

Editorial Boards:

  1. NONE

Patents:

  1. NONE

Publishing Royalties:

  1. NONE

Employment, Commercial Entity:

  1. NONE

Consultancies:

  1. NONE

Speakers’ Bureaus:

  1. NONE

Other Activities:

  1. NONE

Clinical Procedures or Imaging Studies:

  1. NONE

Research Support, Commercial Entities:

  1. National Institutes of Health Veterans Administration

Research Support, Government Entities:

  1. Veterans Administration - Merit Review Veterans Administration - Mental Illness Research Education Clinical Center

Research Support, Academic Entities:

  1. NONE

Research Support, Foundations and Societies:

  1. NONE

Stock/Stock Options/Board of Directors Compensation:

  1. NONE

License Fee Payments, Technology or Inventions:

  1. NONE

Royalty Payments, Technology or Inventions:

  1. NONE

Stock/Stock Options, Research Sponsor:

  1. NONE

Stock/Stock Options, Medical Equipment & Materials:

  1. NONE

Legal Proceedings:

  1. NONE

Abstract

Objectives:

Identifying phenotypes for successful cognitive aging, intact cognition into late-old age (>age 75), can help identify genes and neurobiological systems that may lead to interventions against and prevention of late-life cognitive impairment. The association of C-reactive protein (CRP) with cognitive impairment and dementia, observed primarily in young-elderly samples, appears diminished or reversed in late-old age (75+ years). A family history study determined if high CRP levels in late-old aged cognitively intact probands are associated with a reduced risk of dementia in their first-degree family members, suggesting a familial successful cognitive aging phenotype.

Methods:

The primary sample was 1,329 parents and siblings of 277 cognitively intact male veteran probands at least 75 years old. The replication sample was 202 relatives of 51 cognitively intact community-ascertained probands at least 85 years old. Relatives were assessed for dementia by proband informant interview. Their hazard ratio (HR) for dementia as a function of the proband's log-transformed CRP was calculated using the proportional hazards model.

Results:

Covarying for key demographics, higher CRP in probands was strongly associated with lower risk of dementia in relatives (HR = 0.55 [95% confidence interval (CI) 0.41, 0.74], p < 0.02). The replication sample relationship was in the same direction, stronger in magnitude, and also significant (HR = 0.15 [95% CI 0.06, 0.37], p < 0.0001).

Conclusions:

Relatives of successful cognitive aging individuals with high levels of CRP are relatively likely to remain free of dementia. High CRP in successful cognitive aging individuals may constitute a phenotype for familial—and thus possibly genetic—successful cognitive aging.

Most studies supporting associations of cardiovascular risk factors (CVRFs) with increased risk of subsequent cognitive decline, dementia, and Alzheimer disease (AD)1 derive from young-elderly (<75 years) cohorts. Longitudinal studies at older ages are inconsistent, with some associations in the opposite direction.25 Focusing on successful cognitive aging, remaining cognitively intact into late-old age (>age 75), might help explain these discrepancies. A CVRF associated with subsequent poor cognitive outcome based on young-elderly samples may be called a “putative” risk factor for those in late-old age because generalization would be plausible. Conversely, prevalent successful cognitive aging in those with this putative risk factor may be attributable to countervailing factors—perhaps familial—promoting successful cognitive aging. The putative risk factor in individuals with successful cognitive aging would be testable as a phenotype for successful cognitive aging by examining the extent of successful cognitive aging among their relatives.

C-reactive protein (CRP) is a biomarker for systemic inflammation and a CVRF.6 In longitudinal studies of cognitive healthy subjects at baseline, significant relationships with impaired cognitive function were observed for young cohorts (averaging ≤63 years),79 but not old cohorts (≥77),1013 with mixed results for intermediate cohorts (71 and 74 years).11,1418 Moreover, our group found higher levels of CRP associated with better memory function in cognitively intact individuals over age 75.19 The present study evaluated high CRP as a phenotype for successful cognitive aging by testing the hypothesis that a higher CRP in successful cognitive aging probands is associated with less dementia in parents and siblings.

METHODS

Probands.

The primary convenience sample consisted of cognitively intact, 75+ year old, male veteran outpatients at the JJP-VAMC in the Bronx, New York, enrolled from 2004 through 2010. The Computerized Patient Record System (CPRS) was used for an initial screen to exclude patients carrying a diagnosis of dementia, neurodegenerative disorder (e.g., Parkinson disease), or psychosis, or a history of cerebrovascular accident. Also excluded, regardless of diagnosis, were those prescribed dementia-related medications (e.g., donepezil). Letters were sent to potentially eligible subjects. Volunteers were then assessed both directly and through informants to ensure eligibility (see below). Many of these subjects were also participants in other studies.19,20

Demographics, medical chart review, and health questionnaire.

Collected demographic and health-related information on the probands included age, years of education, marital status, occupation (their own, their spouse's, their father's), and physical activity level across each decade of their adult life. The CPRS provided diagnoses of specific illnesses, particularly diabetes and hypertension. Probands reported on history of tobacco smoking, head injury, and major depression or other serious mental illnesses.

Verification of intact cognition in probands.

The Clinical Dementia Rating scale (CDR)21 assessed 6 domains of cognitive function with probands and with their informants to rate global dementia status. Probands were required to have CDR = 0, indicating absence of even questionable dementia, and also a Mini-Mental State Examination (MMSE)22 score better than the 10th percentile of age- and education-adjusted norms.23 The intact cognitive status of each potential proband was then determined by a clinical consensus conference led by M.S. or H.T.G., both blind to CRP level and family dementia history.

Blood assays.

Probands provided a fasting blood sample for assessment of high sensitivity CRP, in serum using the ADVIA 1650 Chemistry System with a CRP latex reagent, and other CVRFs (e.g., cholesterol, hemoglobin A1c). DNA was extracted and APOE was genotyped to identify those with an ε4 allele. CRP was not normally distributed (skewness = 2.60, kurtosis = 7.40), so the usual logarithmic transformation was employed (skewness = −0.36, kurtosis = −0.49). For descriptive purposes, CRP was categorized into tertiles.

Demographic and cognitive information collection on relatives.

Only parents and siblings of the probands were included in the analyses, since they—but not offspring—were typically elderly. The AD Risk Questionnaire24 was administered to probands to collect information on each relative's birth year, sex, and age (at time of interview or death), and to screen for memory loss or other cognitive. Diagnosis of dementia and age at onset were established by the Dementia Questionnaire administered to the proband.

Statistical methods.

We used the proportional hazards model in the R survival analysis package,25 to evaluate the risk for incident dementia in relatives as a function of their age at onset of dementia. It takes into account the diminishing number of relatives at risk due to censorship by prior death or dementia morbidity, or age at assessment of no dementia status. The package provides robust correction for lack of independence within clusters, so family membership was always included as a random factor in the model. The primary model assessed the association of risk with log-transformed proband CRP—the HR, proband's age, proband's years of education, and relative's sex were additional covariates. We verified the proportional hazards assumption that risk functions for different values of a covariate (including log-transformed CRP) are proportional.25 Additional analyses considered a quadratic CRP model; other covariates, including proband's APOE ε4 status; interactions of CRP with covariates; and subgroups of relatives.

Since there was a single primary hypothesis of association of proband CRP with risk of dementia in relatives, there was no adjustment of its level of significance for multiple comparisons. The Holm procedure for multiple comparisons,26 an enhancement of the Bonferroni procedure, was employed to evaluate the results of additional analyses involving covariates, interactions, and subgroups.

Replication sample.

An independent convenience sample of 85+ year old cognitively intact, community-dwelling probands was ascertained between 2004 and 2010 in the New York area. The same primary and additional analyses as the primary sample were performed, except analyses of relatives of probands with APOE ε4, since there were too few. The sex of the proband was an additional covariate. These subjects, described in detail elsewhere,27 were recruited after talks on memory at senior centers, through newspaper advertisements, and word of mouth. Those without memory concerns were encouraged to volunteer, and were assessed using the same cognitive, family, and blood assessments as the veteran sample. Cognitive status was confirmed in the same consensus conferences as the veterans, but without routine access to medical records.

Standard protocol approvals, registrations, and patient consents.

The study was approved by institutional review boards of the Mount Sinai School of Medicine and the James J. Peters Veterans Affairs Medical Center (JJP-VAMC), with probands providing written informed consent.

RESULTS

Information on relatives and CRP levels were collected on 277 probands from the JJP-VAMC. Table 1 shows characteristics of all probands and relatives, and for each CRP tertile. Sixty percent of probands in the high tertile had values above the normal limit, 3.0 mg/L. There were no significant tertile differences in proband age or proband years of education. APOE genotyping was performed for 259 of the 277 probands, with fewer APOE ε4 carriers found in the highest tertile. We found no differences among proband tertiles in marital status, physical activity level, tobacco use, total cholesterol, triglycerides, hemoglobin A1c, diastolic or systolic blood pressure, the proband's occupation, the spouse's occupation, the father's occupation, the presence of diabetes, hypertension, head injury, or major depression. The relatives of probands in each tertile had similar ages, but there were more males in the lowest tertile.

Table 1
Characteristics of late-old aged cognitively intact male veterans and their relatives

Dementia was identified in 40 relatives from 37 families (3 with 2 cases each). Results from proportional hazards models are presented in table 2. In the primary model, there was significantly decreasing risk of dementia in relatives as proband CRP increased, but no significance of the other primary model covariates. The result excluding the 3 other covariates was similar. Addition of quadratic CRP to the model was not significant. Proband APOE ε4 status was not a significant covariate, and adding it did not change the association with CRP. No interactions of proband CRP with any of these covariates were significant.

Table 2
Proportional hazard model results for primary and additional models in the primary and replication samples

Subsidiary analyses examined the HR for CRP in subgroups of relatives. HRs were similar to the overall result for parents, siblings, and relatives of probands with and without APOE ε4; their lack of significance was attributable to the smaller samples and the more stringent Holm significance criterion. CRP spikes in the presence of some acute and chronic inflammatory conditions excluding the 9 families of probands with CRP >10.0 mg/L did not essentially change the HR for CRP.

We tested whether a higher proband CRP level was associated with greater mortality in relatives, because a reduced rate of dementia might be explained by differentially greater censorship due to mortality among those relatives putatively most vulnerable to dementia. However, replacing dementia by mortality in the primary model, the association of CRP with mortality risk in relatives was not significant, and nominally protective (HR = 0.94 [95% CI 0.084, 1.04], z = −1.11, p = 0.24).

For descriptive purposes, we constructed dementia cumulative risk curves for each tertile using the actuarial life table method. By age 90, the cumulative risks were 0.13, 0.12, and 0.05 for relatives of probands in the low, middle, and high tertiles (figure 1). Discrepancies are small below age 80, but the proportional hazards assumption is not substantively violated because all rates are very low.

Figure 1
Cumulative risk of dementia in relatives of cognitively intact male veteran probands aged 75+ by proband C-reactive protein (CRP) tertile

In the replication sample, the 51 probands had 202 parents and siblings (table e-1 on the Neurology® Web site at www.neurology.org provides descriptive statistics). As in the primary sample, higher CRP was associated with lower risk of dementia in relatives, but this result was more strongly significant (p < 0.0001; table 2). None of the other covariates in the primary model achieved significance by the Holm criterion, and the risk for CRP was not substantially affected by excluding the 3 other covariates. Addition of quadratic CRP to the model was not significant; proband APOE ε4 status was not a significant covariate and it did not affect the CRP association.

For all the subgroups considered for the primary sample, the replication sample hazard rates were not substantially different from the overall hazard rate in the replication sample, and were also statistically significant. There was a significant interaction between CRP and proband's age, but—as for the primary sample—interactions of CRP with relative's sex and proband's years of education were not significant. In the primary sample, all probands were male; the hazard rate for relatives of male probands in the replication sample was similar to the hazard rate in the primary sample. Although the hazard rate for relatives of female probands in the replication sample was nominally smaller, the interaction of proband sex with CRP was not significant. Inclusion of proband sex as a covariate did not change the association with CRP.

DISCUSSION

For the primary sample of cognitively intact, late-old aged (75+ year old) male veterans, high proband CRP level was significantly associated with low dementia risk in their relatives. The relationship was stronger in a smaller, independent, community-ascertained sample of cognitively intact, even older (85+ year old) probands. The similar direction of these results—despite several differences between the samples—nominates high CRP in individuals with successful cognitive aging as a phenotype for familial successful cognitive aging.

For some other CVRFs, putative risk factors in late-old age subjects are associated with their own lower risk of subsequent decline; both samples in this study showed this for risk in relatives. By what mechanism might a risk factor associated with a deleterious effect in young-elderly be associated with a reduced or protective effect in late-old age? Several investigators have proposed that protective genotypes or other protective factors may “buffer” the effects of risk factors, and aging per se, on dementia and death.28,29 A person with such protection may better tolerate the destructive associations of a specific risk factor with both longevity and cognition. The effect on longevity may influence the apparent effect on cognition.

Figure 2 shows a survivor effect model with disparate distributions at different ages of a putative risk factor for protected and nonprotected subjects with intact cognition. By early old age (left side), the risk factor has not yet reached the critical period for the bad outcomes of cognitive decline and death. Thus, those with intact cognition consist of an unprotected majority (red) and a protected minority (blue), with a wide range of risk factor levels in both groups. Over time, CVRF associations with death and cognitive impairment will be readily observed because there are many more unprotected than protected subjects. By late-old age (right side), the protected and unprotected groups have different distributions of the risk factor, due to differential censorship effects of mortality and cognitive impairment. The reduced number of unprotected individuals surviving with intact cognition will tend to have low risk factor levels, which contributed to their survival and intact cognition. In contrast, protected subjects are more likely to survive, and to have intact cognition, even at high risk factor levels. Thus, survivors with intact cognition include relatively more protected individuals than at younger ages. Moreover, proportionately more protected than unprotected survivors have high risk factor levels, unlike at younger ages.

Figure 2
The survivor effect model

In this survival model, at midlife, most subjects will be the more common, unprotected individuals, for whom the risk factor will predict poor subsequent cognition. By late life, unprotected survivors will have risk factor levels that are lower than the midlife population, but those with highest risk factor levels will have highest dementia risk. In contrast, the protected survivors will have low risk of dementia despite a full range of risk factor levels. The increasingly larger proportion of protected individuals, and the lower risk factor levels in unprotected individuals, will reduce the predictive impact of the risk factor.25,30 When the unprotected survivors have higher dementia risk and lower risk factor levels than the protected survivors, the association of the high risk for dementia with lower risk factor levels will reverse the association observed in midlife. Such a reversal of association has been reported for some CVRFs.25,30

As noted above, longitudinal studies of late-old age subjects with no cognitive impairment have not found associations of high CRP with increased or decreased risk for subsequent decline. In apparent contrast, a cross-sectional analysis of dementia in nonagenarians showed higher CRP levels in those with dementia.31 According to the survivor effect model, survivors with dementia would be relatively likely to be unprotected individuals with high risk factors. Moreover, a parallel analysis of incident dementia from the same project showed no association with CRP level.32 Although the model in figure 2 might predict a negative association of CRP with dementia risk at age 90, this refers to cognitively intact survivors. Almost half of the nonagenarian sample without dementia (44%) were cognitively impaired, and thus more likely to be unprotected than cognitively intact survivors. This might increase their association of CRP with dementia risk, counteracting the association in the cognitively intact subjects.

CRP is a biomarker for inflammation, which is generally associated with increased risk of poor cognitive outcomes,33 so the association of CRP with risk of dementia in relatives may not reflect a mechanism involving CRP per se. In contrast to young elderly subjects, in 86+-year-old subjects, genes associated with dementia regulated inflammatory and immune function; in cognitively intact subjects' brains, immune response genes were upregulated, and downregulated in subjects with dementia.34 That study raises the possibility that a more active immune system may have a protective role against dementia specifically in the very old. The CRP findings of the present study are consistent with the relevance of a robust immune function in the very old without dementia, and a familial—and thus possibly genetic—effect.

As seen elsewhere,35 the APOE ε4 allele was less common among the probands in the highest tertile, suggesting a possible association of dementia risk with relatives' APOE ε4 status. The relationship of high proband CRP with low dementia risk in relatives was similar after adding proband APOE ε4 status as a covariate, and in the 2 subgroups of relatives by proband APOE ε4 status. Thus, we found no indication that the CRP/familial risk association is attributable to a possible discrepancy of relatives' APOE ε4 status.

Our study raises methodologic issues requiring consideration. The primary proband sample was comprised only of men, but the older replication sample included both sexes. In the smaller replication sample, the HR for males was similar to the primary sample, and for females it was nominally lower. This suggests that the CRP association observed in the primary sample is not limited to males.

The number of cases is small because the rate of dementia in relatives of late-old aged cognitively intact probands is lower than in the general population.20 Direct assessment of relatives would have enhanced the study, but our method has demonstrated very good reliability36,37 and validity.38,39 Improving on the reliability studies, the proband informant was always a contemporary of the relatives. Direct assessment of all living relatives would be logistically challenging and expensive.

Direct examination of the living relatives would also have permitted measuring their CRP level, but this intervening variable was not critical for the model of association of proband CRP with dementia risk in relatives. The relative's own years of education was not consistently available, so this was not included as a control variable. Among the probands, the partial correlation of years of education and CRP, controlling for age, was small (partial r = 0.07, p = 0.24), suggesting that an association of relatives' CRP with their education is unlikely to be strong enough to account for the association between high proband CRP and low risk for dementia in relatives.

The association between relatively high CRP levels in cognitively intact late-old aged probands and low risk of dementia in relatives links the familiality of successful cognitive aging with discrepant impact of CRP on risk of cognitive decline at different ages. Indeed, other than age itself,20,40 characteristics distinguishing among late-old aged probands without dementia—who therefore demonstrate successful cognitive aging—have not to our knowledge previously distinguished extent of risk for dementia among their relatives. Similar examination of relatives using other CVRFs in the primary proband group will be conducted. This study suggests that, among such probands, relatively high levels of CRP may be a useful biological phenotype for familial successful cognitive aging. This phenotype may help identify relevant genes, leading to development of interventions for maintaining cognitive function.

Supplementary Material

Data Supplement:
Accompanying Editorial:
Abstract in Arabic:

GLOSSARY

AD
Alzheimer disease
CDR
Clinical Dementia Rating
CI
confidence interval
CPRS
Computerized Patient Record System
CRP
C-reactive protein
CVRF
cardiovascular risk factor
HR
hazard ratio
JJP-VAMC
James J. Peters Veterans Affairs Medical Center
MMSE
Mini-Mental State Examination

Footnotes

Editorial, page 1078

Supplemental data at www.neurology.org

AUTHOR CONTRIBUTIONS

Study concept and design: Dr. Silverman. Analysis or interpretation of data: Drs. Silverman, Schmeidler, Beeri, Rosendorff, Sano, and Haroutunian. Drafting/revising the manuscript for content: Drs. Silverman, Schmeidler, Beeri, Grossman, Carrión-Baralt, Bespalova, and Bespalova, R. West, and Dr. Haroutunian. Statistical analysis: Drs. Silverman and Schmeidler. Obtaining funding: Drs. Silverman and Haroutunian.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

REFERENCES

1. Beeri MS, Ravona-Springer R, Silverman JM, Haroutunian V. The effects of cardiovascular risk factors on cognitive compromise. Dialogues Clin Neurosci 2009;11:201–212. [PMC free article] [PubMed]
2. van den Berg E, Biessels GJ, de Craen AJ, Gussekloo J, Westendorp RG. The metabolic syndrome is associated with decelerated cognitive decline in the oldest old. Neurology 2007;69:979–985. [PubMed]
3. Mielke MM, Zandi PP, Sjogren M, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005;64:1689–1695. [PubMed]
4. Reitz C, Tang MX, Manly J, Schupf N, Mayeux R, Luchsinger JA. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement Geriatr Cogn Disord 2008;25:232–237. [PMC free article] [PubMed]
5. Forti P, Pisacane N, Rietti E, et al. Metabolic syndrome and risk of dementia in older adults. J Am Geriatr Soc 2010;58:487–492. [PubMed]
6. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007;49:2129–2138. [PubMed]
7. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002;52:168–174. [PubMed]
8. Teunissen CE, van Boxtel MP, Bosma H, et al. Inflammation markers in relation to cognition in a healthy aging population. J Neuroimmunol 2003;134:142–150. [PubMed]
9. Marioni RE, Stewart MC, Murray GD, et al. Peripheral levels of fibrinogen, C-reactive protein, and plasma viscosity predict future cognitive decline in individuals without dementia. Psychosom Med 2009;71:901–906. [PMC free article] [PubMed]
10. Laurin D, David CJ, Masaki KH, White LR, Launer LJ. Midlife C-reactive protein and risk of cognitive decline: a 31-year follow-up. Neurobiol Aging Epub 2008 Mar 1. [PubMed]
11. Sundelof J, Kilander L, Helmersson J, et al. Systemic inflammation and the risk of Alzheimer's disease and dementia: a prospective population-based study. J Alzheimers Dis 2009;18:79–87. [PubMed]
12. Tan ZS, Seshadri S, Beiser A, et al. Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 2003;163:1053–1057. [PubMed]
13. van den Biggelaar AH, Gussekloo J, de Craen AJ, et al. Inflammation and interleukin-1 signaling network contribute to depressive symptoms but not cognitive decline in old age. Exp Gerontol 2007;42:693–701. [PubMed]
14. Hoth KF, Haley AP, Gunstad J, et al. Elevated C-reactive protein is related to cognitive decline in older adults with cardiovascular disease. J Am Geriatr Soc 2008;56:1898–1903. [PMC free article] [PubMed]
15. Engelhart MJ, Geerlings MI, Meijer J, et al. Inflammatory proteins in plasma and the risk of dementia: the Rotterdam Study. Arch Neurol 2004;61:668–672. [PubMed]
16. Yaffe K, Lindquist K, Penninx BW, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003;61:76–80. [PubMed]
17. Ravaglia G, Forti P, Maioli F, et al. Blood inflammatory markers and risk of dementia: The Conselice Study of Brain Aging. Neurobiol Aging 2007;28:1810–1820. [PubMed]
18. Alley DE, Crimmins EM, Karlamangla A, Hu P, Seeman TE. Inflammation and rate of cognitive change in high-functioning older adults. J Gerontol A Biol Sci Med Sci 2008;63:50–55. [PMC free article] [PubMed]
19. Silverman JM, Beeri MS, Schmeidler J, et al. C-reactive protein and memory function suggest antagonistic pleiotropy in very old nondemented subjects. Age Ageing 2009;38:237–241. [PMC free article] [PubMed]
20. Silverman JM, Schnaider-Beeri M, Grossman HT, Schmeidler J, Wang JY, Lally RC. A phenotype for genetic studies of successful cognitive aging. Am J Med Genet B Neuropsychiatr Genet 2008;147B:167–173. [PubMed]
21. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412–2414. [PubMed]
22. Folstein MF, Folstein SE, McHugh PR. “Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198. [PubMed]
23. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State examination by age and educational level. JAMA 1993;269:2386–2391. [PubMed]
24. Breitner JCS, Folstein MF. Familial Alzheimer's disease: a prevalent disorder with specific clinical features. Psychol Med 1984;14:63–80. [PubMed]
25. Therneau TM. Survival analysis including penalized likelihood. R Package Version 2.19. 2006.
26. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979;6:65–70.
27. Beeri MS, Schmeidler J, Sano M, et al. Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old. Neurology 2006;67:1006–1010. [PMC free article] [PubMed]
28. Bergman A, Atzmon G, Ye K, MacCarthy T, Barzilai N. Buffering mechanisms in aging: A systems approach toward uncovering the genetic component of aging. PLoS Comput Biol 2007;3:1648–1656. [PMC free article] [PubMed]
29. Bathum L, Christiansen L, Jeune B, Vaupel J, McGue M, Christensen K. Apolipoprotein ε genotypes: relationship to cognitive functioning, cognitive decline, and survival in nonagenarians. J Am Geriatr Soc 2006;54:654–658. [PubMed]
30. Euser SM, van BT, Schram MT, et al. The effect of age on the association between blood pressure and cognitive function later in life. J Am Geriatr Soc 2009;57:1232–1237. [PubMed]
31. Kravitz BA, Corrada MM, Kawas CH. Elevated C-reactive protein levels are associated with prevalent dementia in the oldest-old. Alzheimers Dement 2009;5:318–323. [PMC free article] [PubMed]
32. Kravitz BA, Corrada MM, Kawas CH. High levels of serum C-reactive protein are associated with greater risk of all-cause mortality, but not dementia, in the oldest-old: results from The 90+ Study. J Am Geriatr Soc 2009;57:641–646. [PMC free article] [PubMed]
33. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F. Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 2005;4:371–380. [PubMed]
34. Katsel P, Tan W, Haroutunian V. Gain in brain immunity in the oldest-old differentiates cognitively normal from demented individuals. PLoS One 2009;4:e7642. [PMC free article] [PubMed]
35. Hubacek JA, Peasey A, Pikhart H, et al. APOE polymorphism and its effect on plasma C-reactive protein levels in a large general population sample. Hum Immunol 2010;71:304–308. [PMC free article] [PubMed]
36. Silverman JM, Breitner JC, Mohs RC, Davis KL. Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. Am J Psychiatry 1986;143:1279–1282. [PubMed]
37. Silverman JM, Keefe RS, Mohs RC, Davis KL. A study of the reliability of the family history method in genetic studies of Alzheimer disease. Alzheimer Dis Assoc Disord 1989;3:218–223. [PubMed]
38. Li G, Aryan M, Silverman JM, et al. The validity of the family history method for identifying Alzheimer disease. Arch Neurol 1997;54:634–640. [PubMed]
39. Ellis RJ, Jan K, Kawas C, et al. Diagnostic validity of the dementia questionnaire for Alzheimer disease. Arch Neurol 1998;55:360–365. [PubMed]
40. Payami H, Montee K, Kaye J. Evidence for familial factors that protect against dementia and outweigh the effect of increasing age. Am J Hum Genet 1994;54:650–657. [PubMed]

Articles from Neurology are provided here courtesy of American Academy of Neurology